Dr. Reddy's Laboratories announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent
generic version of Cubicin® for Injection, approved by the U.S. Food and Drug Administration (USFDA).
Cubicin® for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health.
Dr. Reddy's Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin. Cubicin is a trademark of Merck Sharp & Dahme Corp.